[Rich66]

Annals of Oncology Advance Access originally published online on March 5, 2009
Annals of Oncology 2009 20(4):796-797; doi:10.1093/annonc/mdp026
© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Zoledronic acid-induced regression of multiple metastases at nonskeletal sites

The first 10% of the full text of this article appears below.

Bisphosphonates have been shown to reduce skeletal complications in individuals with bone metastases secondary to a wide range of solid tumors including lung, breast, and prostate cancer [1]. They are widely administered as palliative agents together with chemotherapy, hormonal therapy, or irradiation [2]. In addition, several types of cancer cells including hematologic malignancies respond to bisphosphonates in . . . [Full Text of this Article]
K. Okamoto, J. Tsurutani^*, M. Terashima, I. Okamoto and K. Nakagawa
Department of Medical Oncology, Kinki University School of Medicine, Osakasayama, Osaka, Japan
^* (E-mail: tsurutani_j@dotd.med.<b><font color=.../b>indai.ac.jp)

	Full Text